SCHEMBL22480486

SCHEMBL22480486

COC(=O)c1cccc(COc2ccc(Cl)cc2C(F)(F)F)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 10/20 1.00
PTGER1 P34995 8/20 0.47
CYP1A2 P05177 3/20 0.47
CYP2C9 P11712 3/20 0.47
TBXA2R P21731 2/20 0.47
PTGS1 P23219 2/20 0.47
CYP2C19 P33261 2/20 0.47
PTGER3 P43115 2/20 0.47
PTGER2 P43116 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22480991 0.88 MRGPRX4 (1.00) MRGPRX4PTGER1CYP1A2CYP2C9TBXA2R
SCHEMBL22480487 0.84 MRGPRX4 (1.00) MRGPRX4PTGER1CYP1A2CYP2C9
SCHEMBL22469616 0.83 MRGPRX4 (0.78) MRGPRX4
SCHEMBL22469980 0.78 MRGPRX4 (1.00) MRGPRX4
SCHEMBL20897473 0.73 MRGPRX4 (0.83) MRGPRX4
SCHEMBL25113756 0.72 PTGER1 (0.60) MRGPRX4PTGER1CYP1A2CYP2C9TBXA2R
SCHEMBL22480420 0.72 MRGPRX4 (1.00) MRGPRX4PTGER1CYP1A2CYP2C9TBXA2R
SCHEMBL22480865 0.72 MRGPRX4 (1.00) MRGPRX4PTGER1CYP1A2CYP2C9
SCHEMBL18003073 0.72 MRGPRX4 (0.56) MRGPRX4CYP1A2
SCHEMBL18003505 0.72 MRGPRX4 (0.56) MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-12-12 US disclosed
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-05-25 US disclosed
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods ESCIENT PHARMACEUTICALS, INC. (US) 2023-05-09 US disclosed
US-20230053860-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2023-02-23 US disclosed
US-20210032213-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS INCYTE CORPORATION 2021-02-04 US disclosed
WO-2020198537-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS ESCIENT PHARMACEUTICALS, INC. (US) 2020-10-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11840521-B2 Modulators of Mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 MRGPRX4 1/4885PTGER1 244/4885CYP1A2 2025/4885
US-11643399-B2 Modulators of mas-related G-protein receptor X4 and related products and methods MRGPRX4, MRGPRX1, MRGPRX2 MRGPRX4 1/4885PTGER1 244/4885CYP1A2 2025/4885
US-20210032213-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 MRGPRX4 1/4885PTGER1 244/4885CYP1A2 1975/4885
US-20230159474-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 MRGPRX4 1/4885PTGER1 244/4885CYP1A2 2025/4885
US-20230053860-A1 MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS MRGPRX4, MRGPRX1, MRGPRX2 MRGPRX4 1/4885PTGER1 244/4885CYP1A2 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.